Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 E332K |
| Therapy | Neratinib |
| Indication/Tumor Type | extrahepatic bile duct carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 E332K | extrahepatic bile duct carcinoma | predicted - sensitive | Neratinib | Case Reports/Case Series | Actionable | In a clinical case study, erlynx (neratinib) treatment resulted in improvement in performance status lasting 4 months in a patient with extrahepatic cholangiocarcinoma harboring ERBB3 E332K (PMID: 33279901). | 33279901 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33279901) | ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. | Full reference... |